Christine Spencer outlines her study investigating the effect of diet and supplements on gut microbiota and response to anti-PD-1 therapy in patients with metastatic melanoma, and discusses how the findings may be relevant to other tumor types (3:43).
On the back of success in melanoma with PD-1 and CTLA-4 checkpoint inhibitors, attention has turned to other checkpoint proteins such as indoleamine 2,3-dioxygenase (IDO). In this editorial, Zeynep Eroglu (Moffitt Cancer Center, USA) discusses the advances and setbacks in the development of IDO inhibitors for melanoma.
In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.
Here we report a comparison between available response criteria when used to evaluate CNS response of patients from a Phase II trial studying the effect of pembrolizumab in patients with previously untreated or progressive melanoma or lung cancer brain metastases.
Qian JM et al. J Neurooncol 2017. doi:10.1007/s11060-017-2398-8